Introduction
============

Maternal mortality remains a significant public health problem in Ecuador ([@B51]; [@B5]; [@B21]). The main cause for maternal mortality is preeclampsia -- a disease characterized by hypertension, increased vascular resistance, endothelial dysfunction, proteinuria, and coagulopathy -- that usually manifests in the second trimester of pregnancy ([@B32]). Preeclampsia is defined as an increase in blood pressure that is equal to or greater than 140/90 mmHg and 24 h of proteinuria equal to or greater than 300 mg/dl ([@B43]). The presence of preeclampsia during pregnancy also causes complications to the newborn and is associated with low birth weight, preterm delivery, and neonatal mortality ([@B28]). However, despite several years of basic research, the genesis and the pathophysiology of preeclampsia still remain unknown ([@B1]).

For several years, we have dedicated our research efforts toward acquiring a better understanding of preeclampsia and designing new strategies, concepts, and hypotheses that might allow us to unlock the enigma of the etiology of preeclampsia ([@B4]). In this paper, we describe the evidence that highlights the putative role of abnormalities in placental implantation and, more specifically, in terms of mitochondrial function at the placental level on the genesis of preeclampsia. The effects of these alterations upon the maternal endothelium are discussed elsewhere ([@B38]; [@B11]; [@B18]; [@B41]).

Development of the Placenta During Normal Pregnancy and in Preeclampsia
=======================================================================

The placenta is a temporary organ that forms a physical and functional connection between the mother and the embryo/fetus during development. However, in contrast to other organs, the environment in which the placenta develops during the first 8--10 weeks is poor in oxygen; it has been demonstrated that this is essential for blastocyst implantation and further embryo and placental development ([@B14]; [@B16]).

The trophoblast cells differentiate into the embryo and are derived from the trophectoderm and develop into the blastocyst during development; these cells are essential in maintaining the further development of a normal pregnancy ([@B14]). The trophoblast adheres to the uterus and begins to penetrate into the endometrial stroma. Previous research has shown that proteolytic enzymes such as metalloproteinase act as facilitators in the penetration process by degrading the extracellular matrix ([@B16]).

The implantation of the blastocyst and primitive placental formation are associated with active penetration of the trophoblast into the endometrial epithelium and adjacent stroma in a low-pressure oxygen environment, which facilitates this process ([@B14]). Subsequently, when the trophoblast is in an environment of high oxygen pressure ([@B14]), it begins the process of differentiation from an early proliferative to an invasive phenotype that will continue to penetrate up to the first third of the myometrium ([@B61]). Interestingly, these cells can also invade the maternal spiraled arteries, which helps to refurbish and replace endothelial and muscular cells ([@B61]). This procedure, known as the conversion, is the replacement of the fetal by maternal endothelium and a loss of elasticity in the arterial vessels. Arteries, then by losing their elasticity, become more compliant, like veins, to increase its capability, according to the demand during pregnancy. In this way, blood flow increases in order to supply nutrients and oxygen to the embryo/fetus during development.

The syncytiotrophoblast is responsible for nutrient exchange, and it is derived from the fusion of the trophoblast cells, which creates an impermeable cellular wallpaper ([@B16]). In addition to the maintenance of the placental nutrients, the syncytiotrophoblast is also responsible for gaseous exchange as well as the production of hormones and growth factors.

Dependence on oxygen is necessary for normal placental development ([@B9]). The processes underlying the differentiation and the invasion of the trophoblast into the endometrium consume significant amounts of energy ([@B58]). Based on this requirement, placental development requires an organ acting as an oxygen sensor to modulate energy production. Experimental studies have demonstrated that mitochondria and, more specifically, respiratory chain complexes appear to be responsible for such regulation ([@B9]).

To determine the mechanisms responsible for how and why the placenta and trophoblastic cells can detect oxygen levels may have significant clinical relevance because preeclampsia or the retardation of intrauterine growth involves changes in placentation.

Abnormal Placentation During Preeclampsia
=========================================

Several studies have shown that an alteration in placental function is linked to the development of preeclampsia. This pathology can occur in pregnancies without a fetus being present, for example, in the condition referred to as mole hydatidiform ([@B35]) or via poor placentation ([@B16]) and thus cause an increase in the placental mass, which is the characteristic of gestational diabetes ([@B43]) or multiple pregnancies ([@B52]). Notably, preeclampsia resolves after delivery ([@B37]). Furthermore, histopathological studies have demonstrated morphological changes in vessels from preeclamptic placentas in a process that has come to be known as "endotheliosis" ([@B15]). A number of experimental studies have analyzed these observations ([@B15]; [@B37]; [@B6]; [@B17]; [@B26]; [@B60]) and have noted that during preeclampsia, there are two functional abnormalities: first, invasion of the trophoblast to the uterine parenchyma is not deeper and invasion to the vasculature does not reach up to the decidua portion and into the spiral arteries. As a consequence, maternal vessels do not complete the normal physiological changes known as conversion. Consequently, the diameter of the myometrial vessels in preeclampsia is less than half of those in normal pregnancy ([@B3]); furthermore, these vessels maintain their responsiveness to vasoconstrictors such as angiotensin or epinephrine ([@B54]). Second, the number of vessels showing evidence of trophoblastic invasion is reduced in comparison with normal pregnancy ([@B23]).

However, there has been significant debate over the potential causes of such alterations. An immunological hypothesis targets a potential maternal sensitization process against fetal tissue. It has been shown that longer sexual cohabitation ([@B10]) and sexual practices that expose the maternal environment to the partner's semen, for example, oral sex or intercourse without a condom ([@B24]), can reduce a women's risk for the further development of preeclampsia ([@B40]).

In the maternal decidua, there is a significant concentration of leucocytes; of these, the most important are the natural killers (NK cells). During preeclampsia, the trophoblast experiences an increased level of cellular lysis by maternal NK cells ([@B6]), which is responsible for an abnormal sensitization process. Therefore, during preeclampsia, there is a reduction in the expression of human leucocyte antigen G (HLA-G) in the invasive trophoblast ([@B6]), making these cells more susceptible to attack by NK cells present in the maternal decidua. This process seems to be maintained throughout pregnancy, meaning that trophoblastic cells do not have the resources to support appropriate implantation. In these cases, the production of lysis enzymes in the extracellular matrix from the maternal decidua is abnormal ([@B26]) and the enzymes produced have structural problems and, therefore, are not able to function appropriately ([@B17]). Consequently, the trophoblast cannot break down the maternal extracellular matrix and, hence, invasion is not possible.

In addition, during the process of placentation, several factors, such as growth factors and intercellular adhesion molecules, control trophoblast differentiation and also the process of conversion. During preeclampsia, these factors and their functions are often abnormal; thus, trophoblast invasion and conversion are also abnormal ([@B60]; [@B16]).

Finally, for all these cellular processes, it is known that the trophoblast requires oxygen to produce energy at the mitochondrial level ([@B14]; [@B9]). Several reports have been now published showing an abnormal mitochondrial function in the trophoblast cells during preeclampsia ([@B13]; [@B55]; [@B56]; [@B39]).

Mitochondria and Preeclampsia
=============================

Mitochondria are intracellular organelles responsible for energy production through the respiratory chain in a process that uses oxygen to form adenosine triphosphate (ATP), which is known as oxidative phosphorylation ([@B8]). This process is characterized by the transport of electrons from NADH and FADH~2~ to the five separate enzymatic complexes in the mitochondrial membrane. Oxygen is the final receptor of electrons at the end of the respiratory chain, where it is ultimately reduced to water. However, during this process, normally 2--3% of oxygen is not completely reduced and leads to the formation of reactive oxygen species (ROS), particularly, superoxide ($\text{O}_{2}^{-}$, 16). Superoxide is mainly generated by coenzyme Q10 (CoQ10) partially reduced -- and by complex III in the respiratory chain ([@B25]). Consequently, superoxide can be converted into hydrogen peroxide by superoxide dismutase in the mitochondria ([@B57]).

Considering the demand for oxygen and energy required for normal placental development, it is logical to assume that any alterations at this level might compromise the overall process of placentation. Indeed, observational studies have demonstrated a higher incidence of preeclampsia in a family with mitochondrial dysfunction ([@B53]). In addition, in women with preeclampsia ([@B12]) and their first-degree relatives, there is an abnormality in the expression of mitochondrial genes responsible for energy production, such as cytochrome C oxidase ([@B30]), or electron exchange processes preferentially favor oxidation ([@B56]). On the contrary, it is well known that hypoxic conditions, for example, living at an altitude, lead to major susceptibility to the development of preeclampsia ([@B59]). In this sense, there is significant evidence showing that increased generation of ROS plays a key role in the development of preeclampsia ([@B7]; [@B2]; [@B31]; [@B29]; [@B27]; [@B44]; [@B42]). Reports have also confirmed that the origin of ROS is most likely from the placenta and, in particular, mitochondria ([@B56]). A previous study reported that the number of mitochondria in placental tissue is far greater in women with preeclampsia and that these mitochondria have greater susceptibility to lipid peroxidation ([@B56]); however, these observations were made in only a small number of patients (Table [1](#T1){ref-type="table"}).

###### 

Studies involving the activity of the mitochondria during preeclampsia.

  Study    Relevant findings
  -------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B53]   Features of preeclampsia as disturbed ion transport and prostaglandin synthesis, vasoconstriction, platelet aggregation, and hyperuricemia may be explain by mitochondrial dysfunction.
  [@B12]   Mutations in mitochondrial transfer ribonucleic acid genes in two families are associated with a high occurrence of preeclampsia and eclampsia.
  [@B30]   Number of mitochondria positive for COX staining markedly decreased in the placentae of the women with preeclampsia.
           Dysfunction of trophoblast's mitochondria may be present in placenta of patients with preeclampsia.
  [@B56]   Increase of the amount of placental mitochondria in preeclampsia.
           Mitochondrial lipid peroxidation increased in preeclampsia.
           Mitochondrial generation of superoxide an important source of oxidative stress in preeclampsia.
  [@B44]   The content of free 8-iso-prostaglandin F2a in decidual tissue from preeclampsia was significantly elevated than in control tissue.
  [@B42]   Oxidative stress in placenta of preeclamptic women is increased.
  [@B59]   Placenta from women living at high altitude has increased villous vascularization and thinning of the villous membranes, that together increases oxygen diffusion capacity.

In this sense, CoQ10, the only non-polar electron transporter into the mitochondrial respiratory chain, plays a key role in both production of energy and formation of ROS ([@B8]; [@B25]). Circulating CoQ10 is known to act as a potent antioxidant, either directly ([@B22]) or via the regeneration of vitamin E ([@B20]). Therefore, it seems logical to suggest that CoQ10 could be involved in the pathogenesis of preeclampsia.

Coenzyme Q10 During Normal Pregnancy and Preeclampsia
=====================================================

The CoQ10 or ubiquinone, is a fat-soluble molecule synthesized endogenously from phenylalanine (benzoquinone ring) and mevalonic acid (responsible for isoprenoid units) and with a small contribution derived from the diet ([@B8]). The CoQ10 participates in energy generation and plays a key role in mitochondrial respiration, as it is responsible for electron transport from complex I and II to complex III ([@B8]). Thus, any alteration in the mitochondrial CoQ10 might result in reduced formation of energy and an increase in generation of ROS ([@B25]). On the contrary, CoQ10 acts as an antioxidant for lipoproteins, both membrane-bound and circulating ([@B20]). In the later environment, the function of CoQ10 is related to its capability to increase the bioavailability of vasoactive substances such as nitric oxide (NO; [@B20]; [@B45]).

Only a few studies have investigated CoQ10 during human pregnancy ([@B33], [@B34]). These studies showed that the levels of CoQ10 increase progressively, starting in the first trimester and continue to rise until delivery (Table [2](#T2){ref-type="table"}). In 2003, the authors' group reported that Ecuadorian normal pregnant women, although with recognized nutritional deficiencies, had CoQ10 levels within the normal range as reported for other populations, but higher than non-pregnant women ([@B49]). However, the authors reported for the first time that women with preeclampsia show a significant reduction in CoQ10 levels ([@B49]), a result that was later confirmed by other authors ([@B36]). At that time, our working hypothesis was that during preeclampsia, there may be a "mechanism" that consumes CoQ10 (not related to diet), which might arise because of increased production of ROS. To investigate further this possibility, the author's group investigated CoQ10 levels in the placenta and the umbilical cord and interestingly found that the levels were significantly higher in women with preeclampsia ([@B50]), suggesting a compensatory accumulation. However, all those studies were done in Quito, a high-altitude city (2800 m above the sea level). So, in a subsequent study, plasma CoQ10 was measured in Ecuadorian women living at sea level; results showed that normal pregnant women had significantly lower levels of CoQ10, but in those with preeclampsia, the difference was not as evident as in those patients living at high altitude; these observations may be related to the small sample size of this study ([@B46]). Interestingly, placental content of CoQ10 was also significantly higher in preeclamptic women at sea level ([@B46]). It was also consistent with a later study showing that CoQ10 levels in mitochondria from placentas of women with preeclampsia were significantly higher compared with mitochondria from normal placentas ([@B48]; Table [2](#T2){ref-type="table"}).

###### 

Studies involving Coenzyme Q10 (CoQ10) during normal pregnancy and preeclampsia.

  Study    Relevant findings
  -------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B33]   Low CoQ10 levels in cases of spontaneous abortion.Increase in the plasma CoQ10 levels in relation to the contractile activity of the uterine muscle.
  [@B34]   CoQ10 levels were higher in fetuses with hypoxia and non-immune hydrops.
  [@B49]   Plasma CoQ10 levels were significantly higher in normal pregnant women in comparison to non-pregnant women.During preeclampsia there is a significant decrease in plasma levels of CoQ10 compared to normal pregnant women.
  [@B36]   In pre-eclampsia there is decreased levels of CoQ10 and alpha-tocopherol, reducing the ability of antioxidant defense leading to the endothelial cell damage observed in preeclampsia.
  [@B50]   CoQ10 in placenta and umbilical cord blood from women with preeclampsia was significantly higher compare to normal pregnancy.
  [@B46]   Plasma and placental CoQ10 levels in normal pregnant women at sea level were significantly lower than in those living at high altitude.Preeclamptic women displayed higher placental CoQ10 content, which was only significant among those living at sea level; while CoQ10 plasma levels were significantly lower only in preeclamptic women living at high altitude.
  [@B47]   Double blind, placebo controlled clinical trial with CoQ10 supplementation (200 mg/daily) from week 20 of pregnancy.Thirty women (25.6%) in the placebo group compared with 17 women (14.4%) in the CoQ10 group developed preeclampsia (*p* = 0.035).
  [@B19]   At week 20 of pregnancy, plasma CoQ10 levels showed no difference between the control and supplemented groups.In the CoQ10 group women who developed preeclampsia showed significantly higher placental levels than normal pregnant women did.In mitochondria from preeclamptic women, levels of CoQ10 were no different among those in the placebo and CoQ10 groups.

According to our present data, it is likely that women with preeclampsia have already-established alterations in their levels of CoQ10 compared with normal pregnant women; these changes occur both in the plasma and the placenta. However, they occur to a greater extent in the mitochondria. However, all of these previous studies were conducted in women, who had already developed the disease; consequently, it was not possible to determine if a reduction in CoQ10 was a cause or a consequence. With this information, we decided to set up a randomized, double-blinded, and placebo-controlled clinical trial providing 200 mg of CoQ10 daily to 235 pregnant women starting from week 20 up to delivery; we then determined the rate of preeclampsia in this cohort of patients. At the end of the study, there were more patients in the preeclampsia placebo group (25.6% vs. 14.4%), demonstrating, also for the first time, that supplementation of CoQ10 represents an effective intervention to reduce the risk of developing preeclampsia ([@B47]).

*Post hoc* analysis showed that before supplementation, at week 20 of pregnancy, plasma CoQ10 levels showed no difference between controls and the supplemented groups. Interestingly, at delivery, placental tissue showed no differences in the placebo group when compared between women with normal pregnancy and those with preeclampsia, while in the CoQ10 group, women with preeclampsia showed significantly higher placental levels compared with normal pregnant women. However, mitochondrial levels of CoQ10 in the placenta from pregnant women with preeclampsia receiving placebo did not show significant differences when compared with those receiving supplementation of CoQ10. These results suggest that in women with preeclampsia, although CoQ10 reduced preeclampsia and was present in high levels in placental tissue, the mitochondrial levels of CoQ10 did not change significantly ([@B19]).

Conclusion
==========

In conclusion, preeclampsia is associated with abnormal placental development as a result of several factors; of these, the dysfunction of the mitochondria appears to be the most important. In that case, the lack of energy and the associated increase of free radicals might be due to the deficiency or the consumption of CoQ10, as supplementation of CoQ10 was shown to be an effective intervention for the reduction of the rate of preeclampsia (Figure [1](#F1){ref-type="fig"}).

![Mitochondria produce energy for placental development during normal pregnancy (green arrow) that is abnormal in preeclamptic women (red dashed arrow). Supplementation of coenzyme Q10 might restore the activity of the mitochondria.](fphys-09-01561-g001){#F1}
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